A distal symmetrical sensory
peripheral neuropathy is frequently observed in people living with Human Immunodeficiency Virus Type 1 (HIV-1). This neuropathy can be associated with
viral infection alone, probably involving a role for the envelope
glycoprotein gp120; or a
drug-induced toxic neuropathy associated with the use of
nucleoside analogue
reverse transcriptase inhibitors as a component of highly active anti-retroviral
therapy. In order to elucidate the mechanisms underlying
drug-induced neuropathy in the context of
HIV infection, we have characterized pathological events in the peripheral and central nervous system following systemic treatment with the anti-retroviral agent, ddC (
Zalcitabine) with or without the concomitant delivery of HIV-gp120 to the rat sciatic nerve (gp120+ddC). Systemic ddC treatment alone is associated with a persistent mechanical
hypersensitivity (33% decrease in limb withdrawal threshold) that when combined with perineural HIV-gp120 is exacerbated (48% decrease in threshold) and both treatments result in thigmotactic (anxiety-like) behaviour. Immunohistochemical studies revealed little ddC-associated alteration in DRG phenotype, as compared with known changes following perineural HIV-gp120. However, the
chemokine CCL2 is significantly expressed in the DRG of rats treated with perineural HIV-gp120 and/or ddC and there is a reduction in intraepidermal nerve fibre density, comparable to that seen in
herpes zoster infection. Moreover, a spinal
gliosis is apparent at times of peak behavioural sensitivity that is exacerbated in gp120+ddC as compared to either treatment alone. Treatment with the microglial inhibitor,
minocycline, is associated with delayed onset of
hypersensitivity to mechanical stimuli in the gp120+ddC model and reversal of some measures of thigmotaxis. Finally, the
hypersensitivity to mechanical stimuli was sensitive to systemic treatment with
gabapentin,
morphine and the
cannabinoid WIN 55,212-2, but not with
amitriptyline. These data suggests that both
neuropathic pain models display many features of HIV- and anti-retroviral-related
peripheral neuropathy. They therefore merit further investigation for the elucidation of underlying mechanisms and may prove useful for preclinical assessment of drugs for the treatment of HIV-related peripheral
neuropathic pain.